Antifungal Agents

  • Wolfgang Graninger
  • Magda Diab-Elschahawi
  • Elisabeth Presterl


In the last 20 years, new and effective antifungal agents with moderate side effects were developed and are now in clinical use. Antifungal treatment was long confined to amphotericin B, but its use is limited because of its nephrotoxicity and systemic side effects. Fluconazole was the first triazole developed for clinical use and is still very much in use because of its moderate interaction with other medication and negligible side effects. Voriconazole, posaconazole and isavuconazole are broad-spectrum triazoles also effective against Aspergillus sp. and other hyphomycetes. Due to their interference with the CYP-P450 enzymes in the liver, there are interactions with other medication which have to be considered when antifungal treatment is initiated. Echinocandin, caspofungin, micafungin and anidulafungin are effective against Candida spp., but there is also some activity against hyphomycetes, e.g. Aspergillus.


  1. 1.
    Imhof A, Walter RB, Schaffner A (2003) Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 36(8):943–951PubMedCrossRefGoogle Scholar
  2. 2.
    Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M et al (2001) Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45(12):3487–3496PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E et al (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44(10):1289–1297PubMedCrossRefGoogle Scholar
  4. 4.
    Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA et al (1997) Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24(2):235–247PubMedCrossRefGoogle Scholar
  5. 5.
    Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhine-Chalberg J et al (1994) Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 18(2):240–242PubMedCrossRefGoogle Scholar
  6. 6.
    Voss A, de Pauw BE (1999) High-dose fluconazole therapy in patients with severe fungal infections. Eur J Clin Microbiol Infect Dis 18(3):165–174PubMedCrossRefGoogle Scholar
  7. 7.
    Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A (1993) Treatment of Candida albicans fungaemia with fluconazole. J Infect 26(2):133–146PubMedCrossRefGoogle Scholar
  8. 8.
    Torres HA, Kontoyiannis DP, Rolston KV (2004) High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study. Support Care Cancer 12(7):511–516PubMedCrossRefGoogle Scholar
  9. 9.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347(6):408–415PubMedCrossRefGoogle Scholar
  10. 10.
    Winston DJ, Busuttil RW (2002) Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 74(5):688–695PubMedCrossRefGoogle Scholar
  11. 11.
    Gonzalez GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi MG, Loebenberg D et al (2003) Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother 47(4):1436–1438PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Herbrecht R (2004) Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 58(6):612–624CrossRefGoogle Scholar
  13. 13.
    Lodge BA, Ashley ED, Steele MP, Perfect JR (2004) Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol 42(3):1376–1378PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Courtney R, Radwanski E, Lim J, Laughlin M (2004) Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 48(3):804–808PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R (2004) Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 48(9):3543–3551PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Negroni R, Helou SH, Petri N, Robles AM, Arechavala A, Bianchi MH (2004) Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 38(3):e15–e20PubMedCrossRefGoogle Scholar
  17. 17.
    Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R et al (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis 63(4):e1–e60PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Kontoyiannis DP, Lewis RE (2011) How I treat mucormycosis. Blood 118(5):1216–1224PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR (2005) Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 40(12):1770–1776PubMedCrossRefGoogle Scholar
  20. 20.
    Gonzalez GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi M, Loebenberg D et al (2002) In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 46(5):1352–1356PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Boucher HW, Groll AH, Chiou CC, Walsh TJ (2004) Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs 64(18):1997–2020PubMedCrossRefGoogle Scholar
  22. 22.
    Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA et al (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387(10020):760–769PubMedCrossRefGoogle Scholar
  23. 23.
    Rybak JM, Marx KR, Nishimoto AT, Rogers PD (2015) Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy 35(11):1037–1051PubMedCrossRefGoogle Scholar
  24. 24.
    Falci DR, Pasqualotto AC (2013) Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist 6:163–174PubMedPubMedCentralGoogle Scholar
  25. 25.
    Mellinghoff SC, Bassetti M, Dorfel D, Hagel S, Lehners N, Plis A et al (2017) Isavuconazole shortens the QTc interval. Mycoses 61(4):256–260CrossRefGoogle Scholar
  26. 26.
    Espinel-Ingroff A (2003) In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20(4):121–136PubMedGoogle Scholar
  27. 27.
    Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M (2003) In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 47(4):1376–1381PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Warn PA, Morrissey G, Morrissey J, Denning DW (2003) Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 51(4):913–919PubMedCrossRefGoogle Scholar
  29. 29.
    Denning DW (2003) Echinocandin antifungal drugs. Lancet 362(9390):1142–1151PubMedCrossRefGoogle Scholar
  30. 30.
    van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407–1416PubMedCrossRefGoogle Scholar
  31. 31.
    Bartlett MS, Current WL, Goheen MP, Boylan CJ, Lee CH, Shaw MM et al (1996) Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 40(8):1811–1816PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T (2004) Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 44(6):590–598PubMedCrossRefGoogle Scholar
  33. 33.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62(4):e1–e50PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Wolfgang Graninger
    • 1
  • Magda Diab-Elschahawi
    • 2
  • Elisabeth Presterl
    • 2
  1. 1.Department of Medicine I, Division of Infectious Diseases and Tropical MedicineMedical University of ViennaViennaAustria
  2. 2.Department of Infection Control and Hospital EpidemiologyMedical University of ViennaViennaAustria

Personalised recommendations